GlassScriptPhysician profile
Nancy J Walden
NPI 1275739245
$4,752.27
in general payments reported to CMS, 2019-2025
21 companies · $1,405 in 2025
The $1,405 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $191 · 2022: $440 · 2023: $1,164 · 2024: $1,552 · 2025: $1,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,121.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,032.67 | 2022-2025 | |
| Novo Nordisk INC | $727.91 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $374.43 | 2023-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $327.67 | 2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $249.81 | 2022-2024 | Airsupra |
| Amgen INC. | $228.54 | 2025 | Evenity |
| Pfizer INC. | $210.79 | 2025 | |
| Abbott Laboratories | $134.89 | 2023 | Proclaim |
| Si-Bone, INC. | $129.68 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $124.99 | 2024 | Austedo Xr |
| Pharmaessentia USA Corporation | $124.99 | 2024 | Besremi |
| Regeneron Healthcare Solutions, INC. | $124.99 | 2025 | Dupixent |
| Viiv Healthcare Company | $124.99 | 2024 | Apretude |
| Phathom Pharmaceuticals, INC. | $124.56 | 2024 | Voquezna |
| Alkermes, INC. | $123.98 | 2025 | Lybalvi |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $123.66 | 2023 | Arexvy |
| E.R. Squibb & Sons, L.L.C. | $109.24 | 2024 | Eliquis |
| Inspire Medical Systems, INC. | $106.64 | 2023 | Inspire |
| Janssen Pharmaceuticals, INC | $105.28 | 2023 | Spravato |
| Aimmune Therapeutics, INC. | $81.32 | 2024 | |
| Eisai INC. | $61.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Walden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.